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Abstract
On November 15th, the scientific world was taken by storm when Chinese researchers announced that the
gene editing technique, CRISPR, was being used for the first time in a clinical trial.i CRISPR, which stands for
clustered regularly interspaced short palindromic repeats, allows scientists to target specific genes for
knockout, or even for replacement by other genes. The technique has showed promising results in both in
vitro and animal models, and researchers foresee myriad medical uses for it. The aforementioned Chinese
study involves genetically engineering T-cells to make them better able to fight cancer. Another CRISPR study
involving reprogramming T-cells was approved by US ethics panels on June 21.ii In what is clearly shaping up
to be a biomedical “race to the cure”, scientists are eager to determine whether CRISPR is a safe, effective
means of treating cancer. If this proves to be the case, CRISPR could soon be used to wage war on genetic
disorders such as cystic fibrosis, or perhaps even autoimmune diseases such as Type I diabetes or multiple
sclerosis.
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On November 15th, the scientific world was taken by storm when Chinese researchers announced that the 
gene editing technique, CRISPR, was being used for the first time in a clinical trial.i CRISPR, which 
stands for clustered regularly interspaced short palindromic repeats, allows scientists to target specific 
genes for knockout, or even for replacement by other genes.  The technique has showed promising results 
in both in vitro and animal models, and researchers foresee myriad medical uses for it.  The 
aforementioned Chinese study involves genetically engineering T-cells to make them better able to fight 
cancer.  Another CRISPR study involving reprogramming T-cells was approved by US ethics panels on 
June 21.ii In what is clearly shaping up to be a biomedical “race to the cure”, scientists are eager to 
determine whether CRISPR is a safe, effective means of treating cancer.  If this proves to be the case, 
CRISPR could soon be used to wage war on genetic disorders such as cystic fibrosis, or perhaps even 
autoimmune diseases such as Type I diabetes or multiple sclerosis. 
While genetic engineering techniques such as TALEN have been around for some time, and have been 
safely used in human patientsiii, CRISPR has been heralded as a much less expensive technique, making 
its use in medicine more cost effective.  In fact, CRISPR kits are now available for use at the 
undergraduate classroom level, proving that the technology is readily available. 
The excitement surrounding CRISPR is widespread throughout the scientific community.  Like any 
technology, CRISPR itself is amoral.  If it proves to be safe, it holds tremendous potential to alleviate or 
possibly even eliminate many genetic disorders.  In the future, it may even be possible to CRISPR edit 
human embryos at a very early developmental stage, so that the resulting child will be born free of genetic 
defects and the resulting developmental deformities that may have ensued. 
With so much at stake, however, the ethical implications of CRISPR cannot be overlooked.  While 
current studies focus on treating disease, CRISPR could certainly be used to edit any gene.  Genetic 
enhancements would certainly be possible.  Treatment of early-stage human embryos with CRISPR raises 
the possibility of germline editing, which means that any errors made in the process of CRISPR therapy 
could be passed to subsequent generations.  While germline editing is still banned in the US,iv many other 
countries, including the UK, have already reversed or are in the process of reversing their bans on such 
editing. 
Human persons are created in the image of God, and therefore worthy of protection and respect.  Genetic 
engineering technology should cause us to question what it means to be human.  Is it possible, using 
genetic means, to change human nature itself?  What risks, inherent in any new procedure, are considered 
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“too high”?  Should germ line therapies ever be permitted, or are the risks to subsequent generations 
simply too great? 
Once again, technology is moving faster than the ethical discussions surrounding its proper and wise 
stewardship.  We dare not wait too long to make our voices heard. 
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